cagrilintide semaglutide trade names Novo Nordisk to present array of new portfolio data including studies with Cagrilintide vs Retatrutide for Weight

For media inquiries, please contact Sara White at [email protected] or 914.621.1323 *These statements have not been evaluated by the Food and Drug Administration

Furthermore, ongoing research is exploring the long-term effects and safety profiles of both medications, which will be critical in guiding future treatment protocols and ensuring optimal patient outcomes

It produces weight loss primarily through appetite suppression and reduced caloric intake, not by accelerating metabolism

The researchers found a lower rate of adverse clinical events in the GLP-1 treated group

[14] Leading medical organizations advise against them

The Direct Hit: A Dedicated GLP-1 Menu Cuba Libre Restaurant & Rum Bar (Old City)